Ontology highlight
ABSTRACT:
SUBMITTER: Kumar SK
PROVIDER: S-EPMC6755968 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
Kumar Shaji K SK Berdeja Jesus G JG Niesvizky Ruben R Lonial Sagar S Laubach Jacob P JP Hamadani Mehdi M Stewart A Keith AK Hari Parameswaran P Roy Vivek V Vescio Robert R Kaufman Jonathan L JL Berg Deborah D Liao Eileen E Rajkumar S Vincent SV Richardson Paul G PG
Leukemia 20190129 7
Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance in NDMM patients. Of 65 enrolled patients, 53 received ixazomib 4 mg (days 1, 8, and 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, and 22) for up to twelve 28-day ind ...[more]